Competing interests
A.V. received a contract from Bristol Myers Squibb to study the mechanism of action of anti-SLAMF7 antibody elotuzumab in multiple myeloma. He also consulted for Boehringer Ingelheim on SIRPα-CD47 blockade. The other author declares no competing interests.
